A phase II study of imatinib with pioglitazone, etoricoxib, dexamethasone, and low-dose treosulfan: Combined anti-inflammatory, immunomodulatory, and angiostatic treatment in patients (pts) with castration-refractory prostate cancer (CRPC)

Reichle, A. and Vogelhuber, M. and Feyerabend, S. and Suedhoff, T. and Schulze, M. and Hubner, J. and Oberneder, R. and Baier, M. and Ruebel, A. and Birkholz, K. and Bakhshandeh-Bath, A. and Andreesen, R. (2011) A phase II study of imatinib with pioglitazone, etoricoxib, dexamethasone, and low-dose treosulfan: Combined anti-inflammatory, immunomodulatory, and angiostatic treatment in patients (pts) with castration-refractory prostate cancer (CRPC). JOURNAL OF CLINICAL ONCOLOGY, 29 (15supp): 4599. ISSN 0732-183X, 1527-7755

Full text not available from this repository.
Item Type: Article
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Depositing User: Petra Gürster
Date Deposited: 30 Apr 2020 06:10
Last Modified: 30 Apr 2020 06:10
URI: https://pred.uni-regensburg.de/id/eprint/20812

Actions (login required)

View Item View Item
pred is powered by EPrints 3.4 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.